BioDelivery Sciences announces primary endpoint in phase 3 study of clonidine not met
BioDelivery Sciences announced the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared to placebo for treatment of painful diabetic neuropathy did not meet statistical significance. A strong safety profile for the product was observed. March 30, 2015